Aqua Bio Technology — Share Issue/Capital Change 2024

Nov 11, 2024

Aqua Bio Technology: Update on resolutions for general meeting - Cancellation of Subsequent Offering

Aqua Bio Technology: Update on resolutions for general meeting - Cancellation of Subsequent Offering

11.11.2024 23:31:20 CET | Aqua Bio Technology ASA | Additional regulated

information required to be disclosed under the laws of a member state

Reference is made to the notice for an extraordinary general meeting in Aqua Bio

Technology ASA (the "Company") published on 23 October 2024, and to the private

placement of new shares in the Company (the "Private Placement") that was

announced placed on 18 October, and to the contemplated subsequent offering of

new shares following the Private Placement (the "Subsequent Offering").

The Company's auditor has prepared an independent expert report in connection

with the Private Placement, which is attached to this stock exchange notice, and

forms part of the decision material for the general meeting. In connection with

the Private Placement, the Board has also amended its proposal with respect to

the Private Placement where the share capital shall be increased with NOK

98,408,672.50 through issuance of 39,363,469 new shares, i.e. one share less

than stated in the notice for the extraordinary general meeting. The reason for

the amended proposal is an updated counting of certain receivables to be

converted to new shares in the Private Placement.

Further, the Board of the Company has decided to withdraw the proposal for share

capital increase in connection with the Subsequent Offering of up to 2,000,000

new shares, as in the period following announcement of the Private Placement it

has been traded more than 2,000,000 shares in the Company over the stock

exchange and at lower average prices than the subscription price in the

Subsequent Offering of NOK 3 per share. Shareholders that have wanted to limit

their dilution following the Private Placement has thus been able to do so

through purchase of shares in the open market.

For further information, please contact Jan Varming, CFO, telephone +47 90 83 90

This information is subject of the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

About Aqua Bio Technology ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skincare products. ABT's cosmetics ingredients are

highly effective, and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skincare products developed by partners towards consumers and

professional users. ABT's focus on commercialization and development of natural

ingredients and natural skincare products has been, and will continue to be, an

important part of the Company's strategy going forward. ABT is listed on the

Euronext Expand market of the Oslo Stock Exchange.

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section

of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Jan Aas Varming, CFO, Aqua Bio Technology ASA, +47 908 39 076,

jan@aquabiotech.no

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/18319603/5231/Download%20announce

ment%20as%20PDF.pdf

Sakkyndig_redegjorelse_ved_kapitalforhoyelse_ved_motregning_Aqua_Bio_Technology_

ASA_11-11-2024.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/18319603/5230/Sakkyndig_redegjore

lse_ved_kapitalforhoyelse_ved_motregning_Aqua_Bio_Technology_ASA_11-11-2024.pdf